Breaking News, Collaborations & Alliances

Nuron Biotech Licenses Alzheimer’s Vax Candidate

Will be responsible for development and commercialization

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Nuron Biotech has licensed a gene-based amyloid beta 42 (Aβ42) vaccine from Vitruvian BioMedical. The vaccine candidate is in preclinical development for Alzheimer’s disease (AD). Nuron has an exclusive, worldwide license for the vaccine and is responsible for development and commercialization. The vaccine is designed to stimulate an immune response in which antibodies that bind to and significantly reduce amyloid beta are produced. Financial terms were not disclosed.   “This unique, promising v...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters